fully human mAb (Oryzon)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namefully human mAb (Oryzon)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCarcinoma, Squamous Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesOryzon Genomics Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOryzon Genomics Sa
Active IndicationsN/A
Inactive IndicationsCarcinoma, Squamous Cell

Other Information

ATC CodeN/A
Related LinksN/A